STUDY QUESTION: What is the impact of the EuroNet-PHL-C2 treatment protocol for children with classical Hodgkin lymphoma (cHL) on gonadal function in girls, based on assessment of serum anti-Müllerian hormone (AMH)? SUMMARY ANSWER: Serum AMH levels decreased after induction chemotherapy and increased during subsequent treatment and 2 years of follow-up, with lowest levels in patients treated for advanced stage cHL. WHAT IS KNOWN ALREADY: Treatment for cHL, particularly alkylating agents and pelvic irradiation, can be gonadotoxic and result in premature reduction of primordial follicles in females. The current EuroNet-PHL-C2 trial aims to reduce the use of radiotherapy in standard childhood cHL treatment, by intensifying chemotherapy. This study aims to assess the gonadotoxic effect of the EuroNet-PHL-C2 protocol. STUDY DESIGN, SIZE, DURATION: This international, prospective, multicenter cohort study is embedded in the EuroNet-PHL-C2 trial, an European phase-3 treatment study evaluating the efficacy of standard cHL treatment with OEPA-COPDAC-28 (OEPA: vincristine, etoposide, prednisone, and doxorubicin; COPDAC-28: cyclophosphamide, vincristine, prednisone, and dacarbazine) versus intensified OEPA-DECOPDAC-21 (DECOPDAC-21: COPDAC with additional doxorubicin and etoposide and 25% more cyclophosphamide) in a randomized setting. Participants were recruited between January 2017 and September 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Female patients aged ≤18 years, treated according to the EuroNet-PHL-C2 protocol for cHL were recruited across 18 sites in the Netherlands, Belgium, Germany, Austria, and Czech Republic. All parents and patients (aged ≥12 years old) provided written informed consent. Serum AMH levels and menstrual cycle characteristics were evaluated over time (at diagnosis, one to three times during treatment and 2 up to 5 years post-diagnosis) and compared between treatment-levels (TL1, TL2, and TL3) and treatment-arms (OEPA-COPDAC-28 and OEPA-DECOPDAC-21). Serum samples obtained from patients after receiving pelvic radiotherapy were excluded from the main analyses. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 104 females, with median age at diagnosis of 15.6 years (IQR 13.7; 17.0), were included in the analysis. Ninety-nine were (post)pubertal. Eighteen girls were diagnosed with an early stage of cHL (TL1) and 86 with intermediate or advanced stage disease (50 TL2 and 36 TL3, 66% received COPDAC-28 and 34% DECOPDAC-21). Five patients received pelvic radiotherapy. Median AMH level at diagnosis was 1.7 µg/l (IQR 0.9; 2.7). After two courses of OEPA chemotherapy, AMH levels decreased substantially in all patients (98% <0.5 µg/l), followed by a significant increase during the consolidation treatment and follow-up. After 2 years, 68% of patients reached their baseline AMH value, with overall median recovery of 129% (IQR 75.0; 208.9) compared to baseline measurement. Five patients (7%) had AMH <0.5 µg/l. In patients treated for advanced stage disease, AMH levels remained significantly lower compared to early- or intermediate stage disease, with median serum AMH of 1.3 µg/l (IQR 0.8; 2.1) after 2 years. Patients who received DECOPDAC-21 consolidation had lower AMH levels during treatment than patients receiving COPDAC-28, but the difference was no longer statistically significant at 2 years post-diagnosis. Of the 35 postmenarchal girls who did not receive hormonal co-treatment, 19 (54%) experienced treatment-induced amenorrhea, two girls had persisting amenorrhea after 2 years. LIMITATIONS, REASONS FOR CAUTION: The studied population comprises young girls with diagnosis of cHL often concurring with pubertal transition, during which AMH levels naturally rise. There was no control population, while the interpretation of AMH as a biomarker during childhood is complex. The state of cHL disease may affect AMH levels at diagnosis, potentially complicating assessment of AMH recovery as a comparison with baseline AMH. The current analysis included data up to 2-5 years post-diagnosis. WIDER IMPLICATIONS OF THE FINDINGS: The current PANCARE guideline advises to use the cyclophosphamide-equivalent dose score (CED-score, as an estimation of cumulative alkylating agent exposure) with a cut-off of 6000 mg/m2 to identify females aged <25 years at high risk of infertility. All treatment-arms of the EuroNet-PHL-C2 protocol remain below this cut-off, and based on this guideline, girls treated for cHL should therefore be considered low-risk of infertility. However, although we observed an increase in AMH after chemotherapy, it should be noted that not all girls recovered to pre-treatment AMH levels, particularly those treated for advanced stages of cHL. It remains unclear how our measurements relate to age-specific expected AMH levels and patterns. Additional (long-term) data are needed to explore clinical reproductive outcomes of survivors treated according to the EuroNet-PHL-C2 protocol. STUDY FUNDING/COMPETING INTEREST(S): The fertility add-on study was funded by the Dutch charity foundation KiKa (project 257) that funds research on all forms of childhood cancer. C.M-K., D.K., W.H.W., D.H., M.C., A.U., and A.B. were involved in the development of the EuroNet-PHL-C2 regimen. The other authors indicated no potential conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

Cancer Center Amsterdam Treament and quality of life Amsterdam UMC Vrije Universiteit Amsterdam The Netherlands

Clinic for Paediatric and Adolescent Medicine Medical Faculty of the Martin Luther University of Halle Halle Germany

Department of Epidemiology and Data Science Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

Department of Haematology Oncology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands

Department of Haematology Oncology Royal Hospital for Sick Children Edinburgh UK

Department of Paediatric Haemato Oncology Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Department of Paediatric Haematology and Oncology KU Leuven UZ Leuven Leuven Belgium

Department of Pediatric Hematology and Oncology Faculty Hospital Motol and 2nd Medical Faculty Charles University Prague Czech Republic

Department of Pediatric Hematology and Oncology Universitätsklinikum Giessen und Marburg GmbH Standort Giessen Zentrum für Kinderheilkunde und Jugendmedizin Giessen Germany

Department of Reproductive Medicine and Gynecology University Medical Center Utrecht Utrecht The Netherlands

Institut für Medizinische Informatik Statistik und Epidemiologie Universität Leipzig Leipzig Germany

Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Wien Austria

Pediatric Oncology Cancer Center Amsterdam Emma Children's Hospital Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands

See more in PubMed

Absolom K, Eiser C, Turner L, Ledger W, Ross R, Davies H, Coleman R, Hancock B, Snowden J, Greenfield D; Late Effects Group Sheffield. Ovarian failure following cancer treatment: current management and quality of life. Hum Reprod  2008;23:2506–2512. PubMed

Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, Peccatori F.  Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update  2022;28:417–434. PubMed PMC

Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, Roberts T, Hatton C, Kalakonda N, Milligan DW  et al.  Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol  2018;19:1328–1337. PubMed PMC

Anderson RA, Su HI.  The clinical value and interpretation of anti-Müllerian Hormone in women with cancer. Front Endocrinol (Lausanne) 2020;11:574263. PubMed PMC

Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, et al.  Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials. J Clin Oncol  2013;31:231–239. PubMed

Berjeb KK, Debbabi L, Braham M, Zemni Z, Chtourou S, Hannachi H, Hamdoun M, Ayadi M, Kacem K, Zhioua F, et al.  Evaluation of ovarian reserve before and after chemotherapy. J Gynecol Obstet Hum Reprod  2020;50:102035. PubMed

Boltežar L, Pintarić K, Jezeršek Novaković B.  Fertility in young patients following treatment for Hodgkin’s lymphoma: a single center survey. J Assist Reprod Genet  2016;33:325–333. PubMed PMC

Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM.  Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update  2014;20:688–701. PubMed

Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WHB.  Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study. J Clin Endocrinol Metab  2012;97:2059–2067. PubMed

Decanter C, Delepine J, Behal H, Manier S, Bruno B, Barbatti M, Robin C, Labreuche J, Morschhauser F, Pigny P.  Longitudinal study of AMH variations in 122 adolescents and young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling. Hum Reprod  2021;36:2743–2752. PubMed

Dorp W, VanVries ACH, DePluijm SMF, Visser JA, Pieters R, Laven JSE, Dorp W, vanHeuvel-Eibrink MM, van denVries AC, dePluijm SMF, et al.  Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. Hum Reprod  2014;29:337–342. PubMed

Drechsel K, Pilon M, Stoutjesdijk F, Meivis S, Schoonmade LJ, Wallace W, Dulmen-den Broeder E, vanBeishuizen A, Kaspers G, Broer S, et al.  Reproductive ability in survivors of childhood, adolescent and young adult Hodgkin lymphoma: a review. Hum Reprod Update  2023a;29:486–517. PubMed PMC

Drechsel KCE, Broer SL, Stoutjesdijk FS, Twisk JWR, Berg MH, van denLambalk CB, Leeuwen FE, vanOverbeek A, Heuvel-Eibrink MM, van denDorp W, et al.; LATER-VEVO Study Group .  Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma. J Cancer Res Clin Oncol  2023b;149:13677–13695. PubMed PMC

Elchuri SV, Patterson BC, Brown M, Bedient C, Record E, Wasilewski-Masker K, Mertens AC, Meacham LR.  Low anti-Müllerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy. J Pediatr Adolesc Gynecol  2016;29:393–399. PubMed

European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL). Second international inter-group study for classical Hodgkin lymphoma in children and adolescent: EuroNet-PHL-C2, 2015. https://classic.clinicaltrials.gov/ct2/show/NCT02684708 (24 February 2024, date last accessed).

Fong SL, Laven JSE, Hakvoort-Cammel FGAJ, Schipper I, Visser JA, Themmen APN, De Jong FH, Van Den Heuvel-Eibrink MM.  Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod  2009;24:982–990. PubMed

Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava DK, Leisenring WM, Neglia JP, Sklar CA, Kaste SC, Hudson MM, et al.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study. Pediatr Blood Cancer  2014;61:53–67. PubMed PMC

Hagen CP, Aksglaede L, Sørensen K, Mouritsen A, Andersson AM, Petersen JH, Main KM, Juul A.  Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod  2012;27:861–866. PubMed

IBM Corp. IBM SPSS Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp, 2021. https://www.ibm.com/support/pages/how-cite-ibm-spss-statistics-or-earlier-versions-spss.

Irene Su H, Kwan B, Whitcomb BW, Shliakhsitsava K, Dietz AC, Stark SS, Martinez E, Sluss PM, Sammel MD, Natarajan L.  Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH. J Clin Endocrinol Metab  2020;105:2740–2751. PubMed PMC

Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP.  Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril  2016;105:765–772e4. PubMed PMC

Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB.  A validated model of serum anti-Müllerian hormone from conception to menopause. PLoS One  2011;6:e22024. PubMed PMC

Krawczuk-Rybak M, Leszczynska E, Poznanska M, Zelazowska-Rutkowska B, Wysocka J.  Anti-Müllerian hormone as a sensitive marker of ovarian function in young cancer survivors. Int J Endocrinol  2013;2013:125080. PubMed PMC

Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP.  Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer  2012;118:1933–1939. PubMed PMC

Li HWR, Ng EHY, Wong BPC, Anderson RA, Ho PC, Yeung WSB.  Correlation between three assay systems for anti-Müllerian hormone (AMH) determination. J Assist Reprod Genet  2012;29:1443–1446. PubMed PMC

Lie Fong S, Visser JA, Welt CK, Rijke YBD, Eijkemans MJC, Broekmans FJ, Roes EM, Peters WHM, Hokken-Koelega ACS, Fauser BCJM, et al.  Serum anti-Müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab  2012;97:4650–4655. PubMed PMC

Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M  et al.  Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol  2022;23:125–137. PubMed PMC

Meirow D.  Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol  2000;169:123–131. PubMed

Mulder RL, Font-Gonzalez A, Green DM, Loeffen EAH, Hudson MM, Loonen J, Yu R, Ginsberg JP, Mitchell RT, Byrne J, et al.; PanCareLIFE Consortium. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol  2021a;22:e57–e67. PubMed

Mulder RL, Font-Gonzalez A, Hudson MM, Santen HM, vanLoeffen EAH, Burns KC, Quinn GP, Dulmen-den Broeder E, vanByrne J, Haupt R, et al.; PanCareLIFE Consortium. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol  2021b;22:e45–e56. PubMed

Oktem O, Kim SS, Selek U, Schatmann G, Urman B.  Ovarian and uterine functions in female survivors of childhood cancers. Oncologist  2018;23:214–224. PubMed PMC

Revelli A, Biasoni V, Gennarelli G, Canosa S, Dalmasso P, Benedetto C.  IVF results in patients with very low serum AMH are significantly affected by chronological age. J Assist Reprod Genet  2016;33:603–609. PubMed PMC

Schaapveld M, Aleman BMP, Eggermond AM, VanJanus CPM, Krol ADG, Maazen RWM, Van DerRoesink J, Raemaekers JMM, Boer JP, DeZijlstra JM, et al.  Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med  2015;373:2499–2511. PubMed

Sonigo C, Beau I, Binart N, Grynberg M.  The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage. Int J Mol Sci  2019;20:5342. PubMed PMC

Spears N, Lopes F, Stefansdottir A, Rossi V, Felici M, DeAnderson RA, Klinger FG.  Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update  2019;25:673–693. PubMed PMC

van de Loo LEXM, van den Berg MH, Overbeek A, van Dijk M, Damen L, Lambalk CB, Ronckers CM, van den Heuvel-Eibrink MM, Kremer LCM, van der Pal HJ, et al.; DCOG LATER-VEVO Study Group. Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. Fertil Steril  2019;111:372–380. PubMed

Van Den Berg MH, Overbeek A, Lambalk CB, Kaspers GJL, Bresters D, Van Den Heuvel-Eibrink MM, Kremer LC, Loonen JJ, Van Der Pal HJ, Ronckers CM, et al.; DCOG LATER-VEVO Study Group.Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Human Reproduction  2018;33:1474–1488. PubMed

van Dijk M, van Leeuwen FE, Overbeek A, Lambalk CB, van den Heuvel-Eibrink MM, van Dorp W, Tissing WJ, Kremer LC, Loonen JJ, Versluys B, et al.  Pregnancy, time to pregnancy and obstetric outcomes among female childhood cancer survivors: results of the DCOG LATER-VEVO study. J Res Clin Oncol  2020;146:1451–1462. PubMed PMC

Wallace WHB, Kelsey TW.  Human ovarian reserve from conception to the menopause. PLoS One  2010;5:e8772. PubMed PMC

Wallace WHB, Thomson AB, Kelsey TW.  The radiosensitivity of the human oocyte. Hum Reprod  2003;18:117–121. PubMed

Wallace WHB, Thomson AB, Saran F, Kelsey TW.  Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys  2005;62:738–744. PubMed

Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, Keizer-Schrama M, De S, Hogervorst E, et al.  ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod  2016;31:926–937. PubMed

Yates AP, Jopling HM, Burgoyne NJ, Hayden K, Chaloner CM, Tetlow L.  Paediatric reference intervals for plasma anti-Müllerian hormone: comparison of data from the Roche Elecsys assay and the Beckman Coulter Access assay using the same cohort of samples. Ann Clin Biochem  2019;56:536–547. PubMed PMC

Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol